Navigation Links
Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
Date:11/15/2012

HAYWARD, Calif., Nov. 15, 2012 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the simultaneous completion of two financings with total proceeds of $210 million, the largest sum to be raised by a private biotechnology company in at least 25 years. The financings consisted of $160 million in proceeds from a preferred stock private placement and $50 million in proceeds from a private debt placement. Investors in these financings included existing investors New Enterprise Associates, Inc., New Leaf Venture Partners and Venrock, as well as new investors, The Baupost Group, LLC, Farallon Capital Management, LLC and three additional top-tier institutional investors based in Boston and New York.

(Logo: http://photos.prnewswire.com/prnh/20050301/SFTU126LOGO)

As a result of these transactions, Intarcia has retained full strategic and financial control of its lead product candidate ITCA 650 (continuous subcutaneous delivery of exenatide), which, if approved, would be the first and only once-yearly, injection-free GLP-1 therapy for the treatment of type 2 diabetes. Intarcia intends to initiate the global Phase 3 program for ITCA 650 in the first quarter of 2013 with its strategic partner Quintiles, Inc., the world's leading biopharmaceutical service provider, which has helped develop or commercialize 18 of the 20 best-selling diabetes products.

"With this landmark financing in place, we have fully preserved the vision for our company and our aim to bring potentially revolutionary clinical, economic and humanistic benefits to millions of diabetes patients around the world," said Kurt Graves, Chairman, President and Chief Executive Officer of Intarcia. "After considering multiple options to maximize shareholder value and scaling up for our ITCA 650 Phase 3 program, we chose to align with this elite group of investors who not only sh
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intarcia Announces Expanded Appointment for Kurt Graves as Chairman, President and Chief Executive Officer
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... YORK , March 3, 2015 Fried, ... Jeffrey I.D. Lewis has joined the Firm ... resident in the New York ... handles trademark matters, as well as other intellectual property ... patent attorney, Mr. Lewis represents both plaintiffs and defendants ...
(Date:3/3/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... Expert Opinion on Biological Therapy , Dr. ... Zhang , at the Henry Ford Hospital in ... 4 (TB4) has the capacity to promote CNS and ... post-injury, leading to neurological recovery in each case.  They ...
(Date:3/3/2015)... 3, 2015 AtheroNova Inc. (OTCQB: AHRO) today announced ... voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code ... California , Santa Ana division ... 11 cases are expected to be jointly administered. ... supervised asset sale process, for all or substantially all of ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Genedata, ... drug discovery and life science research, today announced ... (TM) enterprise platform for use at Pfizer biopharma ... Europe. Genedata is supporting Pfizer’s global deployment and ... (GBT), Centers for Therapeutic Innovation (CTI), and Pharmaceutical ...
Breaking Biology Technology:Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 2AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 4Genedata Biologics Licensed by Pfizer Inc. 2Genedata Biologics Licensed by Pfizer Inc. 3
... Calif., Feb. 11 MannKind Corporation (Nasdaq: ... quarter financial results on Tuesday, February 17, 2009.Management of ... the fourth quarter financial results, clinical progress and other ... 17, 2009. Presenting from the Company will be its ...
... in biological research and drug discovery are bracing for ... LLC ( www.gene2drug.com ), the premier research and advisory ... data from the company,s newest report Prospering ... In this report, we set out to understand ...
... QUEBEC, Feb. 11 /PRNewswire-FirstCall/ - Victhom Human Bionics Inc., ... patent application for the detection and treatment of a ... death in epileptic patients during seizure. , Victhom has ... and device aimed at preventing sudden unexpected death in ...
Cached Biology Technology:MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009 2Life Science Labs Reacting to the Economic Crisis 2Victhom announces the filing of a patent application to address sudden unexplained death in epilepsy (SUDEP) 2Victhom announces the filing of a patent application to address sudden unexplained death in epilepsy (SUDEP) 3
(Date:2/18/2015)... -- Cepheid (NASDAQ: CPHD ) today announced that its ... investors to participate via webcast. , Cowen and Company ... March 3, 2015 at 11.20 a.m. Eastern Time , ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern Time ... for these events, please visit Cepheid,s website at http://ir.cepheid.com ...
(Date:2/12/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announced today ... DISTRIBUTED METHOD AND SYSTEM TO IMPROVE COLLABORATIVE SERVICES ... NXT-ID,s position in the emerging "Internet of Things" by ... multiple devices to collaborate with one another to improve ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America ... methods for carbon nanotube (CNT) macrostructures, including sheets, yarns ... Dallas (UTD). Leveraging the vast industrial resources ... Tokyo, Japan , Lintec of America is forming ... Richardson, TX , focusing on scaling up the ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... Ind. - An animal study at Purdue University has shown ... help the body absorb helpful compounds and also demonstrates the ... animals needed for these types of studies. Mario Ferruzzi, ... model with human intestinal cells to show that adding ascorbic ...
... Haven, Conn.The large group of segmented worms known as annelids, ... years ago and can be found in every corner of ... animal groups on the planet, scientists have struggled to understand ... to each other in terms of their evolutionary history. Now ...
... a plant used a century ago during the great Spanish ... in killing the H1N1 swine flu virus that now threatens ... cooked, but when raw it has sap so foul-smelling that ... report is scheduled for the Sept. 25 issue of ACS, ...
Cached Biology News:Model backs green tea and lemon claim, lessens need to test animals 2Scientists use microRNAs to track evolutionary history for first time 2
RNA oligomers from 10 to 50 bases purified by PAGE and MS-checked. RNAs are supplied dried and fully deprotected....
... Incubator/Shaker HT is designed for ... Incubator/Shaker HT is ideal for ... and primer extension assays. The ... as a one-cabinet model, allowing ...
... Anti-Reverse Cap Analog (ARCA) is a ... OH group (closer to m7G) is replaced ... RNA polymerase can only initiate transcription with ... incorporation in the forward orientation. As a ...
...
Biology Products: